TSX:LABS - Post Discussion
Post by
alleyesonme on Mar 27, 2024 5:05pm
Revenue ramping up/ B2B, contract manufacturing..
Pidduck....."In the last several months, we have signed a number of new B2B international and domestic supply agreements, including deals with leading pharma companies in Brazil and several leading medical cannabis companies in Australia. In Canada, with industry consolidation, we have seen renewed interest regarding B2B quality-focused manufacturing opportunity. Together, these deals could represent over $10 million in annual revenue potential.".......Strachan, "In 2024, Dronabinol will be a big part of our growth in German sales. In 2023, we sold just under $100,000 of this product, mostly for partner R&D. At this point, in 2024, we have already shipped this product to 3 customers and our sales and open orders are already over $1.5 million.
Be the first to comment on this post